Sean M Devlin

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5650949/publications.pdf

Version: 2024-02-01

215 papers	8,688 citations	117625 34 h-index	51608 86 g-index
217 all docs	217 docs citations	217 times ranked	14649 citing authors

#	Article	IF	Citations
1	Antithymocyte globulin exposure in CD34+ T-cellâ€“depleted allogeneic hematopoietic cell transplantation. Blood Advances, 2022, 6, 1054-1063.	5.2	12
2	Reduced Plasmacytoid Dendritic Cell Output Is Associated With High Risk in Low-grade Myelodysplastic Syndrome. HemaSphere, 2022, 6, e685.	2.7	4
3	Impact of TP53 Genomic Alterations in Large B-Cell Lymphoma Treated With CD19-Chimeric Antigen Receptor T-Cell Therapy. Journal of Clinical Oncology, 2022, 40, 369-381.	1.6	60
4	Impact of omitting post-transplant minidose-methotrexate doses in allogeneic hematopoietic cell transplantation. Leukemia and Lymphoma, 2022, 63, 1686-1693.	1.3	2
5	Ionizing radiation exposure after allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation, 2022, 57, 827-829.	2.4	2
6	Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy. Nature Medicine, 2022, 28, 713-723.	30.7	117
7	Stopping rules for phase I clinical trials with dose expansion cohorts. Statistical Methods in Medical Research, 2022, 31, 334-347.	1.5	2
8	Low-dose unfractionated heparin prophylaxis is a safe strategy for the prevention of hepatic sinusoidal obstruction syndrome after myeloablative adult allogenic stem cell transplant. Bone Marrow Transplantation, 2022, 57, 1095-1100.	2.4	4
9	Evaluation of Melphalan Exposure in Lymphoma Patients Undergoing BEAM and Autologous Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy, 2022, 28, 485.e1-485.e6.	1.2	0
10	MAIT and VÎ´2 unconventional T cells are supported by a diverse intestinal microbiome and correlate with favorable patient outcome after allogeneic HCT. Science Translational Medicine, 2022, 14, .	12.4	19
11	Molecular International Prognostic Scoring System for Myelodysplastic Syndromes. , 2022, 1, .		259
12	Ixazomib and dexamethasone in high risk smoldering multiple myeloma: a clinical and correlative pilot study. Leukemia and Lymphoma, 2022, 63, 2760-2761.	1.3	1
13	Engraftment kinetics after transplantation of double unit cord blood grafts combined with haplo-identical CD34+ cells without antithymocyte globulin. Leukemia, 2021, 35, 850-862.	7.2	8
14	Letermovir for Prevention of Cytomegalovirus Reactivation in Haploidentical and Mismatched Adult Donor Allogeneic Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis. Transplantation and Cellular Therapy, 2021, 27, 85.e1-85.e6.	1.2	25
15	Fecal microbiota diversity disruption and clinical outcomes after auto-HCT: a multicenter observational study. Blood, 2021, 137, 1527-1537.	1.4	42
16	Concordance probability as a meaningful contrast across disparate survival times. Statistical Methods in Medical Research, 2021, 30, 816-825.	1.5	0
17	Interplay between chromosomal alterations and gene mutations shapes the evolutionary trajectory of clonal hematopoiesis. Nature Communications, 2021, 12, 338.	12.8	64
18	Laboratory evaluation of folate deficiency among inpatients with cancer. International Journal of Laboratory Hematology, 2021, 43, O164-O167.	1.3	0

#	Article	IF	Citations
19	The International Prognostic Index Is Associated with Outcomes in Diffuse Large B Cell Lymphoma after Chimeric Antigen Receptor T Cell Therapy. Transplantation and Cellular Therapy, 2021, 27, 233-240.	1.2	24
20	Tailored treatment to MRD response: A phase I/II study for newly diagnosed multiple myeloma patients using high dose twiceâ€weekly carfilzomib (45 and 56â€‰mg/m‹sup›2‹/sup›) in combination with lenalidomide and dexamethasone. American Journal of Hematology, 2021, 96, E193-E196.	4.1	10
21	Phase I Clinical Trials in Adoptive T-Cell Therapies. Journal of the Royal Statistical Society Series C: Applied Statistics, 2021, 70, 815-834.	1.0	4
22	Therapeutic Efficacy of Combined JAK1/2, Pan-PIM, and CDK4/6 Inhibition in Myeloproliferative Neoplasms. Clinical Cancer Research, 2021, 27, 3456-3468.	7.0	12
23	Oncologic immunomodulatory agents in patients with cancer and COVID-19. Scientific Reports, 2021, 11, 4814.	3.3	11
24	Oral Proteasome Inhibitor Ixazomib for Switch-Maintenance Prophylaxis of Recurrent or Late Acute and Chronic Graft-versus-Host Disease after Day 100 in Allogeneic Stem Cell Transplantation. Transplantation and Cellular Therapy, 2021, 27, 920.e1-920.e9.	1.2	1
25	Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial. Lancet Haematology,the, 2021, 8, e422-e432.	4.6	50
26	The post-transplant scoring system (PTSS) is associated with outcomes in patients with MDS after CD34+selected allogeneic stem cell transplant. Bone Marrow Transplantation, 2021, 56, 2749-2754.	2.4	0
27	Universal Engraftment after Allogeneic Hematopoietic Cell Transplantation Using Cryopreserved CD34-Selected Grafts. Transplantation and Cellular Therapy, 2021, 27, 697.e1-697.e5.	1.2	7
28	Predictors of Humoral Response to SARS-CoV-2 Vaccination after Hematopoietic Cell Transplantation and CAR T-cell Therapy. Blood Cancer Discovery, 2021, 2, 577-585.	5.0	44
29	Disease- and Therapy-Specific Impact on Humoral Immune Responses to COVID-19 Vaccination in Hematologic Malignancies. Blood Cancer Discovery, 2021, 2, 568-576.	5.0	62
30	Relapse after Allogeneic Stem Cell Transplantation of Acute Myelogenous Leukemia and Myelodysplastic Syndrome and the Importance of Second Cellular Therapy. Transplantation and Cellular Therapy, 2021, 27, 771.e1-771.e10.	1.2	17
31	Fractionated Infusion of Hematopoietic Progenitor Cells Does Not Improve Neutrophil Recovery or Survival in Allograft Recipients. Transplantation and Cellular Therapy, 2021, 27, 852.e1-852.e9.	1.2	0
32	Pediatric-inspired chemotherapy incorporating pegaspargase is safe and results in high rates of minimal residual disease negativity in adults up to age 60 with Philadelphia chromosome-negative acute lymphoblastic leukemia. Haematologica, 2021, 106, 2086-2094.	3.5	24
33	MAIT and VÎ2 Unconventional T Cells Predict Favorable Outcome after Allogeneic HCT and Are Supported By a Diverse Intestinal Microbiome. Blood, 2021, 138, 331-331.	1.4	2
34	Nutrition As a Predictor of Microbiome Injury in Allo-HCT. Blood, 2021, 138, 746-746.	1.4	0
35	Identifying prognostic pairwise relationships among bacterial species in microbiome studies. PLoS Computational Biology, 2021, 17, e1009501.	3.2	0
36	Timing and Immune Status after Cellular Therapies Predict Response to COVID-19 Vaccines. Blood, 2021, 138, 3891-3891.	1.4	1

#	Article	IF	Citations
37	Post-Transplant Cyclophosphamide Is Associated with Improved Clinical Outcomes in HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation. Blood, 2021, 138, 1814-1814.	1.4	0
38	Phase I First-in-Class Trial of MCARH109, a G Protein Coupled Receptor Class C Group 5 Member D (GPRC5D) Targeted CAR T Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma. Blood, 2021, 138, 827-827.	1.4	23
39	Daratumumab Versus Lenalidomide Maintenance Therapy for Multiple Myeloma: A Randomized Pilot Study Comparing Patient-Reported Health Related Quality of Life Measures. Blood, 2021, 138, 4762-4762.	1.4	0
40	TP53 and CD19-Directed Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Large B-Cell Lymphoma. Blood, 2021, 138, 710-710.	1.4	1
41	Pilot Study of Bortezomib and Dexamethasone Pre- and Post-Risk-Adapted Autologous Stem Cell Transplantation in AL Amyloidosis. Biology of Blood and Marrow Transplantation, 2020, 26, 204-208.	2.0	10
42	Favorable long-term outcomes of hematopoietic stem cell transplantation for CMML with myeloablative conditioning, anti-thymocyte globulin, and CD34+ selected graft. Bone Marrow Transplantation, 2020, 55, 1632-1634.	2.4	0
43	Impact of geriatric vulnerabilities on allogeneic hematopoietic cell transplantation outcomes in older patients with hematologic malignancies. Bone Marrow Transplantation, 2020, 55, 157-164.	2.4	39
44	Incidence and Risk Factors for Acute and Chronic Kidney Injury after Adult Cord Blood Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, 758-763.	2.0	14
45	Evaluation of Cord Blood Total Nucleated and CD34+ Cell Content, Cell Dose, and 8-Allele HLA Match by Patient Ancestry. Biology of Blood and Marrow Transplantation, 2020, 26, 734-744.	2.0	14
46	Impact and safety of chimeric antigen receptor T-cell therapy in older, vulnerable patients with relapsed/refractory large B-cell lymphoma. Haematologica, 2020, 106, 255-258.	3.5	38
47	Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma. Blood Cancer Journal, 2020, 10, 79.	6.2	137
48	Measuring the temporal prognostic utility of a baseline risk score. Lifetime Data Analysis, 2020, 26, 856-871.	0.9	0
49	Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nature Medicine, 2020, 26, 1549-1556.	30.7	372
50	Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies. Blood Advances, 2020, 4, 3776-3787.	5.2	162
51	Cancer therapy shapes the fitness landscape of clonal hematopoiesis. Nature Genetics, 2020, 52, 1219-1226.	21.4	367
52	Impact of allogeneic hematopoietic cell transplantation on immune evasive mechanisms in relapsed refractory large B-cell lymphoma. Bone Marrow Transplantation, 2020, 55, 2331-2334.	2.4	0
53	Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell Transplantation. New England Journal of Medicine, 2020, 382, 822-834.	27.0	435
54	Lack of a significant pharmacokinetic interaction between letermovir and calcineurin inhibitors in allogeneic HCT recipients. Bone Marrow Transplantation, 2020, 55, 1687-1689.	2.4	9

#	Article	IF	Citations
55	The geriatric syndrome of sarcopenia impacts allogeneic hematopoietic cell transplantation outcomes in older lymphoma patients. Leukemia and Lymphoma, 2020, 61, 1833-1841.	1.3	9
56	Characteristics and Impact of Post-Transplant Interdisciplinary Palliative Care Consultation in Older Allogeneic Hematopoietic Cell Transplant Recipients. Journal of Palliative Medicine, 2020, 23, 1653-1657.	1.1	1
57	Stem Cell Mobilization and Autograft Minimal Residual Disease Negativity with Novel Induction Regimens in Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2020, 26, 1394-1401.	2.0	8
58	Molecular Predictors and Effectiveness of Measurable Residual Disease (MRD) Eradication with Chemotherapy and Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia. Blood, 2020, 136, 18-20.	1.4	3
59	The microbe-derived short-chain fatty acids butyrate and propionate are associated with protection from chronic GVHD. Blood, 2020, 136, 130-136.	1.4	97
60	Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Patients with Multiple Myeloma Treated with Continuous Lenalidomide Maintenance Therapy: A Clinical and Correlative Phase 2 Study. Blood, 2020, 136, 18-19.	1.4	0
61	Clonal Hematopoiesis and COVID-19 Severity in Cancer Patients. Blood, 2020, 136, 37-38.	1.4	1
62	A Pilot Study Evaluating Lenalidomide and CC-486 in Combination with Radiotherapy for Patients with Plasmacytoma (LENAZART study). Blood, 2020, 136, 8-10.	1.4	0
63	Machine Learning for Prediction of Cancer-Associated Venous Thromboembolism. Blood, 2020, 136, 37-37.	1.4	1
64	Clinical Impact of Bridging Therapy Prior to Commercial Chimeric Antigen Receptor (CAR) T-Cell Therapies for Relapsed/Refractory Lymphomas. Blood, 2020, 136, 1-2.	1.4	1
65	Interplay between Chromosomal Alterations and Gene Mutations Shapes the Evolutionary Trajectory of Clonal Hematopoiesis. Blood, 2020, 136, 29-30.	1.4	0
66	Secondary Graft-Versus-Host Disease (GVHD) Prophylaxis with Oral Proteasome Inhibitor Ixazomib Is Associated with Low Incidence of Recurrent, Late Acute and Chronic GVHD and Facilitated Calcineurin Inhibitor Taper within the First Year Post Allogeneic Stem Cell Transplantation. Blood, 2020, 136, 41-42.	1.4	0
67	Association of Patient Activity Bioprofiles with Hrqol and Clinical Responses: A Prospective Novel Trial Using Mobile Wearables in Newly Diagnosed Multiple Myeloma Patients. Blood, 2020, 136, 26-28.	1.4	2
68	Rabbit Anti-Thymocyte Globulin Exposure (rATG) in CD34+ Selected Hematopoietic Cell Transplantation and Its Impact on Immune Reconstitution and Outcomes in Children and Adults. Blood, 2020, 136, 30-31.	1.4	0
69	End-of-life care for older AML patients relapsing after allogeneic stem cell transplant at a dedicated cancer center. Bone Marrow Transplantation, 2019, 54, 700-706.	2.4	8
70	CD97 is a critical regulator of acute myeloid leukemia stem cell function. Journal of Experimental Medicine, 2019, 216, 2362-2377.	8.5	24
71	Feasibility of a patient-reported, electronic geriatric assessment tool in hematopoietic cell transplantation â€“ a single institution pilot study. Leukemia and Lymphoma, 2019, 60, 3308-3311.	1.3	6
72	Association of Immune Marker Changes With Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma. JAMA Oncology, 2019, 5, 1293.	7.1	57

#	Article	IF	Citations
73	Drugs as a Frequent Cause of Acute Rash in Patients after CD34+-Selected Peripheral Blood Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 2172-2180.	2.0	3
74	Molecular and cytogenetic characteristics of myeloid malignancies following luminal gastrointestinal cancer. Leukemia Research, 2019, 82, 19-23.	0.8	0
75	Baseline identification of clonal V(D)J sequences for DNA-based minimal residual disease detection in multiple myeloma. PLoS ONE, 2019, 14, e0211600.	2.5	24
76	A Phase Ib/II Study of the Histone Methyltransferase Inhibitor Pinometostat in Combination with Azacitidine in Patients with 11q23-Rearranged Acute Myeloid Leukemia. Blood, 2019, 134, 2655-2655.	1.4	11
77	Plasmacytoid Dendritic Cell Proportion Is Predictive of Risk and Outcomes in Myelodysplastic Syndromes. Blood, 2019, 134, 5439-5439.	1.4	3
78	VTE Rates and Safety Analysis of Newly Diagnosed Multiple Myeloma Patients Receiving Carfilzomib-Lenalidomide-Dexamethasone (KRD) with or without Rivaroxaban Prophylaxis. Blood, 2019, 134, 1835-1835.	1.4	7
79	Impact and Safety of Chimeric Antigen Receptor T Cell Therapy in Vulnerable Older Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma. Blood, 2019, 134, 1603-1603.	1.4	5
80	RAS Mutations Are Independently Associated with Decreased Overall Survival and Event-Free Survival in Patients with AML Receiving Induction Chemotherapy. Blood, 2019, 134, 18-18.	1.4	8
81	Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Multiple Myeloma Patients Treated with Lenalidomide Maintenance Therapy: A Clinical and Correlative Phase 2 Study. Blood, 2019, 134, 3127-3127.	1.4	2
82	Easix and Modified-Easix Are Early Predictors of Severe Cytokine Release Syndrome and Neurotoxicity in Patients Treated with Chimeric Antigen Receptor T Cells. Blood, 2019, 134, 1947-1947.	1.4	2
83	Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy Provides Unprecedented MRD Negativity Rates in Newly Diagnosed Multiple Myeloma: A Clinical and Correlative Phase 2 Study. Blood, 2019, 134, 862-862.	1.4	34
84	Safety and Efficacy of Combined Ruxolitinib and Thalidomide in Patients with Myelofibrosis: A Phase II Study. Blood, 2019, 134, 4163-4163.	1.4	25
85	TP53 State Dictates Genome Stability, Clinical Presentation and Outcomes in Myelodysplastic Syndromes. Blood, 2019, 134, 675-675.	1.4	17
86	Dynamic Easix Scores Closely Predict Non-Relapse Mortality after Allogeneic Hematopoietic Cell Transplantation. Blood, 2019, 134, 1971-1971.	1.4	0
87	The Geriatric Syndrome of Sarcopenia Impacts Allogeneic Hematopoietic Cell Transplantation Outcomes in Combination with Multi-Morbidity and Functional Impairment. Blood, 2019, 134, 4508-4508.	1.4	0
88	Difference in Involved and Uninvolved Free Light Chain (dFLC) of Less Than 1mg/DL Early Post Risk Adapted Melphalan and Autologous Stem Cell Transplantation (RA-ASCT) Predicts Renal Response at 1 Year in Light Chain (AL) Amyloidosis. Blood, 2019, 134, 4577-4577.	1.4	0
89	Hematological Count Recovery in Patients Undergoing Treatment with Chimeric Antigen Receptor T Cells (CAR T). Blood, 2019, 134, 4455-4455.	1.4	0
90	Extended Mutational Profiling By MSK-IMPACTTM Identifies Mutations Predicting Thromboembolic Risk in Patients with Solid Tumor Malignancy. Blood, 2019, 134, 633-633.	1.4	1

#	Article	IF	Citations
91	Comparing Gradings of Immune Effector Cells Toxicities: Application of Astct Consensus Grading System and Implications for Clinical Management. Blood, 2019, 134, 4458-4458.	1.4	0
92	Pegaspargase-related high-grade hepatotoxicity in a pediatric-inspired adult acute lymphoblastic leukemia regimen does not predict recurrent hepatotoxicity with subsequent doses. Leukemia Research, 2018, 66, 49-56.	0.8	29
93	Widespread use of measurable residual disease in acute myeloid leukemia practice. Leukemia Research, 2018, 67, 92-98.	0.8	6
94	A phase 1 study of ibrutinib in combination with R-ICE in patients with relapsed or primary refractory DLBCL. Blood, 2018, 131, 1805-1808.	1.4	49
95	Revaccination after Autologous Hematopoietic Stem Cell Transplantation Is Safe and Effective in Patients with Multiple Myeloma Receiving Lenalidomide Maintenance. Biology of Blood and Marrow Transplantation, 2018, 24, 871-876.	2.0	35
96	Validation of an Algorithm to Predict the Likelihood of an 8/8 HLA-Matched Unrelated Donor at Search Initiation. Biology of Blood and Marrow Transplantation, 2018, 24, 1057-1062.	2.0	15
97	CD34+ Cell Selection versus Reduced-Intensity Conditioning and Unmodified Grafts for Allogeneic Hematopoietic Cell Transplantation in Patients Age >50 Years with Acute Myelogenous Leukemia and Myelodysplastic Syndrome. Biology of Blood and Marrow Transplantation, 2018, 24, 964-972.	2.0	19
98	Predictive biomarkers and practical considerations in the management of carfilzomib-associated cardiotoxicity. Leukemia and Lymphoma, 2018, 59, 1981-1985.	1.3	16
99	Disease characteristics and clinical outcomes in patients aged less than 40 with chronic lymphocytic leukemia. Leukemia Research, 2018, 65, 80-85.	0.8	2
100	Predictive factors of fatal bleeding in acute promyelocytic leukemia. Thrombosis Research, 2018, 164, S98-S102.	1.7	16
101	Pretransplant comprehensive geriatric assessment in hematopoietic cell transplantation: a single center experience. Bone Marrow Transplantation, 2018, 53, 1184-1187.	2.4	21
102	Impact of Toxicity on Survival for Older Adult Patients after CD34+ Selected Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 142-149.	2.0	16
103	Effects of Late Toxicities on Outcomes in Long-Term Survivors of Ex-Vivo CD34+-Selected Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 133-141.	2.0	11
104	Autologous CD19-Targeted CAR T Cells in Patients with Residual CLL following Initial Purine Analog-Based Therapy. Molecular Therapy, 2018, 26, 1896-1905.	8.2	65
105	A Simple Geriatric Vulnerability Index for Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation. Blood, 2018, 132, 2176-2176.	1.4	1
106	Safety and Efficacy of Combined Ruxolitinib and Thalidomide in Patients with Myelofibrosis: Initial Results of a Phase II Study. Blood, 2018, 132, 354-354.	1.4	7
107	Safe and Effective Use of Rivaroxaban for Treatment of Cancer Associated Venous Thromboembolic Disease. Blood, 2018, 132, 2536-2536.	1.4	2
108	Depth of Response and Outcomes in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation. Blood, 2018, 132, 4619-4619.	1.4	4

#	Article	IF	Citations
109	MRD-Response Driven Phase I/II Study for Newly Diagnosed Multiple Myeloma Patients Using Higher Doses of Twice-Weekly Carfilzomib (45 and 56 mg/m2) in Combination with Lenalidomide and Dexamethasone. Blood, 2018, 132, 1983-1983.	1.4	2
110	Oncologic Therapy for Solid Tumors Alters the Risk of Clonal Hematopoiesis. Blood, 2018, 132, 747-747.	1.4	3
111	Homebound Autologous Hematopoietic Cell Transplantation for Plasma Cell Disorders in an Urban Setting Is Safe for Patients and Preferred By Patients and Caregivers. Blood, 2018, 132, 2258-2258.	1.4	2
112	HLA-a*0101 Expression Correlates with Increased Risk of Severe Cutaneous Acute Graft-Versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2018, 132, 4564-4564.	1.4	0
113	Impact of Pre-Transplant Rituximab on Efficacy of Revaccination of Lymphoma Patients after Autologous Hematopoietic Stem Cell Transplantation. Blood, 2018, 132, 4592-4592.	1.4	0
114	Rash in Patients after T-Cell-Depleted Peripheral Blood Stem Cell Transplantation: Eosinophilia and Pruritus Do Not Distinguish Acute Graft-Versus-Host Disease from Drug Rash. Blood, 2018, 132, 4570-4570.	1.4	0
115	Dysgeusia Is Associated with Higher Melphalan Pharmacokinetic Levels and Results in Poorer Caloric Intake and Worse Symptom Burden after Autologous Stem Cell Transplantation for Multiple Myeloma. Blood, 2018, 132, 2136-2136.	1.4	0
116	Molecular Predictors and Current Management of Minimal Residual Disease (MRD) Following Induction Chemotherapy for Acute Myeloid Leukemia (AML). Blood, 2018, 132, 292-292.	1.4	1
117	Intestinal Microbiota Composition Is Associated with Minimal Residual Disease Negativity in Patients with Multiple Myeloma. Blood, 2018, 132, 3167-3167.	1.4	1
118	Cancer-Associated Thrombosis: Anatomic Distribution of the Index Event Is Not a Reliable Predictor of Recurrence Risk. Blood, 2018, 132, 1252-1252.	1.4	1
119	Evaluation of Cord Blood (CB) Unit TNC & CD34+ Cell Content & Donor-Recipient High-Resolution 8 HLA-Allele Match By Patient Ancestry: An Evaluation of 513 CB Units in a Racially & Ethnically Diverse Population of Adults with Hematologic Malignancies. Blood, 2018, 132, 3342-3342.	1.4	0
120	Pre-Transplant and Peri-d100 Gastrointestinal Dysbiosis Is Associated with the Subsequent Development of Chronic Graft-Versus-Host Disease. Blood, 2018, 132, 359-359.	1.4	1
121	V(D)J Sequence Capture for DNA-Based Minimal Residual Disease Detection in Multiple Myeloma. Blood, 2018, 132, 4444-4444.	1.4	0
122	A High Degree of Engrafting Unit-Recipient HLA-Allele Mismatch Is Not Associated with an Increased Risk of Transplant-Related Mortality (TRM) or Inferior Progression-Free Survival (PFS) after Double Unit Cord Blood (CB) Transplantation (dCBT) in Adults with Hematologic Malignancies. Blood, 2018, 132, 3470-3470.	1.4	0
123	Double-Unit Cord Blood (CB) Transplantation with Haplo-Identical CD34+ Cells (haplo-dCBT) May Speed Neutrophil Recovery Although Successful Bridging Is Contingent on Close Haplo-Winning CB Unit HLA-Match. Blood, 2018, 132, 2078-2078.	1.4	3
124	Gain of chromosome 1q portends worse prognosis in multiple myeloma despite novel agent-based induction regimens and autologous transplantation. Leukemia and Lymphoma, 2017, 58, 1823-1831.	1.3	57
125	The association of maximum Troponin values post out-of-hospital cardiac arrest with electrocardiographic findings, cardiac reperfusion procedures and survival to discharge: A sub-study of ROC PRIMED. Resuscitation, 2017, 111, 82-89.	3.0	2
126	Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era. Blood, 2017, 129, 1763-1767.	1.4	78

#	Article	IF	Citations
127	Prospective Evaluation of Unrelated Donor Cord Blood and Haploidentical Donor Access Reveals Graft Availability Varies by Patient Ancestry: Practical Implications for Donor Selection. Biology of Blood and Marrow Transplantation, 2017, 23, 965-970.	2.0	31
128	Immunophenotypic evidence for reactive polyclonal marrow plasmacytosis in multiple myeloma patients receiving lenalidomide maintenance. Leukemia and Lymphoma, 2017, 58, 2962-2965.	1.3	4
129	Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nature Medicine, 2017, 23, 703-713.	30.7	2,473
130	Proteomic profiling in plasma cell disorders: a feasibility study. Leukemia and Lymphoma, 2017, 58, 1757-1759.	1.3	7
131	Multicolor Flow Cytometry and Multigene Next-Generation Sequencing Are Complementary and Highly Predictive for Relapse in Acute Myeloid Leukemia after Allogeneic Transplantation. Biology of Blood and Marrow Transplantation, 2017, 23, 1064-1071.	2.0	124
132	Ex Vivo CD34+â€“Selected T Cellâ€“Depleted Peripheral Blood Stem Cell Grafts for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Leukemia and Myelodysplastic Syndrome Is Associated with Low Incidence of Acute and Chronic Graft-versus-Host Disease and High Treatment Response. Biology of Blood and Marrow Transplantation, 2017, 23, 452-458.	2.0	35
133	Outcomes after inferior vena cava filter placement in cancer patients diagnosed with pulmonary embolism: risk for recurrent venous thromboembolism. Journal of Thrombosis and Thrombolysis, 2017, 44, 489-493.	2.1	16
134	The Impact of Toxicities on First-Year Outcomes after Ex Vivo CD34+â€“Selected Allogeneic Hematopoietic Cell Transplantation in Adults with Hematologic Malignancies. Biology of Blood and Marrow Transplantation, 2017, 23, 2004-2011.	2.0	11
135	Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes. Cell Stem Cell, 2017, 21, 374-382.e4.	11.1	578
136	Hematopoietic Cell Transplantation Comorbidity Index Predicts Outcomes in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes Receiving CD34 + Selected Grafts for Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2017, 23, 67-74.	2.0	24
137	Boomerang: A Method for Recursive Reclassification. Biometrics, 2016, 72, 995-1002.	1.4	0
138	The potential benefit of allogeneic over autologous transplantation in patients with very early relapsed and refractory follicular lymphoma with prior remission duration of â‰¤12Âmonths. British Journal of Haematology, 2016, 173, 260-264.	2.5	12
139	Phase IB study of cabozantinib in patients with relapsed and/or refractory multiple myeloma. Blood, 2016, 127, 2355-2356.	1.4	13
140	Treatment outcomes and secondary cancer incidence in young patients with hairy cell leukaemia. British Journal of Haematology, 2016, 175, 402-409.	2.5	26
141	Telomere length and associations with somatic mutations and clinical outcomes in acute myeloid leukemia. Leukemia Research, 2016, 49, 62-65.	0.8	17
142	Mutational correlates of response to hypomethylating agent therapy in acute myeloid leukemia. Haematologica, 2016, 101, e457-e460.	3.5	30
143	Hypoalbuminemia is significantly associated with increased clearance time of high dose methotrexate in patients being treated for lymphoma or leukemia. Annals of Hematology, 2016, 95, 2009-2015.	1.8	41
144	Increased GVHD-related mortality with broad-spectrum antibiotic use after allogeneic hematopoietic stem cell transplantation in human patients and mice. Science Translational Medicine, 2016, 8, 339ra71.	12.4	404

#	Article	IF	Citations
145	Statistical Interactions from a Growth Curve Perspective. Human Heredity, 2016, 82, 21-36.	0.8	3
146	Success of an International Learning Health Care System inÂHematopoietic Cell Transplantation: The American Society of Blood and Marrow Transplantation Clinical Case Forum. Biology of Blood and Marrow Transplantation, 2016, 22, 564-570.	2.0	8
147	CD34-Selected Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Relapsed, High-Risk Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2016, 22, 258-267.	2.0	21
148	T-cell Exhaustion in Multiple Myeloma Relapse after Autotransplant: Optimal Timing of Immunotherapy. Cancer Immunology Research, 2016, 4, 61-71.	3.4	152
149	A Pediatric-Inspired Regimen Containing Multiple Doses of Intravenous Pegylated Asparaginase Appears Safe and Effective in Newly Diagnosed Adult Patients with Ph-Negative Acute Lymphoblastic Leukemia in Adults up to Age 60: Results of a Multi-Center Phase II Clinical Trial. Blood, 2016, 128, 1629-1629.	1.4	6
150	Outcomes of Pharmacokinetically Targeted Busulfan-Based Conditioning Regimen for Patients with Myelodysplastic Syndrome and Acute Myelogenous Leukemia Undergoing CD34 Selected Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2016, 128, 3392-3392.	1.4	1
151	TP53 Mutations in AML Predict Adverse Outcome in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant. Blood, 2016, 128, 3481-3481.	1.4	3
152	Mutational Analysis of Clonal Hematopoiesis in Solid Tumor Patients Illustrates the Critical Role of Systemic Anti-Cancer Therapies in the Evolution of Somatic Leukemia Disease Alleles. Blood, 2016, 128, 37-37.	1.4	16
153	RAS Pathway Mutations Are Associated with Proliferative Features and Frequently Co-Occur with TET2 mutationsin Philadelphia Negative MPN Subtypes. Blood, 2016, 128, 4269-4269.	1.4	1
154	Multicolor Flow Cytometry and Multi-Gene Next Generation Sequencing Are Complimentary and Highly Predictive for Relapse in Acute Myeloid Leukemia Following Allogeneic Hematopoietic Stem Cell Transplant. Blood, 2016, 128, 834-834.	1.4	2
155	Prevalence of clonal hematopoiesis in patients with advanced cancer.. Journal of Clinical Oncology, 2016, 34, 1511-1511.	1.6	0
156	Outcomes of patients 60 and older with ALL: Analysis of the SEER Database.. Journal of Clinical Oncology, 2016, 34, 7021-7021.	1.6	0
157	Comparable Survival and Incidence of Toxicity for Older Adult Patients after CD34+ Selected Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2016, 128, 1236-1236.	1.4	0
158	A Comprehensive Analysis of Late Toxicities and Associated Risk Factors in Long-Term Survivors of Myeloablative Conditioned Allogeneic Hematopoietic Cell Transplantation Using Ex-Vivo CD34+ Selection-Based Graft-Versus-Host Disease Prophylaxis. Blood, 2016, 128, 4621-4621.	1.4	0
159	Allogeneic Hematopoietic Stem Cell Transplantation Is Underutilized in Patients with Myelodysplastic Syndromes. Blood, 2016, 128, 3188-3188.	1.4	0
160	Despite Increasing Size of Unrelated Donor (URD) Registries and the Global Cord Blood (CB) Inventory Racial Disparities in Access to URD and CB Grafts Persist: A Prospective 10 Year Analysis of 1,112 Patients. Blood, 2016, 128, 821-821.	1.4	0
161	An Analysis of Early Toxicities, Associated Risk Factors and Survival during the First Year in Adults Undergoing Ex-Vivo CD34+ Selected Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies. Blood, 2016, 128, 2194-2194.	1.4	0
162	Comparison of Standard Assays (Serum Immunofixation and Protein Electrophoresis) with Hevylite Assay in Patients with Multiple Myeloma. Blood, 2016, 128, 5626-5626.	1.4	0

#	Article	IF	Citations
163	Incidence, Severity, Day 100 Treatment Efficacy and Therapy Toxicity of Cytomegalovirus (CMV) Infections with Early Pre-Emptive Therapy in Adult Cord Blood (CB) Transplant Recipients. Blood, 2016, 128, 2219-2219.	1.4	0
164	A Novel Intermediate Intensity Conditioning Regimen Achieves High Rates of Long-Term Outpatient Progression-Free Survival Offsetting the Disadvantage of Early Post-Transplant Complications in Adult Cord Blood (CB) Transplant Recipients. Blood, 2016, 128, 2193-2193.	1.4	1
165	Impact of Treatment Center Characteristics on Early Death Rates in Patients with Newly Diagnosed Acute Promyelocytic Leukemia: Analysis of Data from the SEER Program. Blood, 2016, 128, 4008-4008.	1.4	0
166	High day 28 ST2 levels predict for acute graft-versus-host disease and transplant-related mortality after cord blood transplantation. Blood, 2015, 125, 199-205.	1.4	109
167	Melanoma and nonâ€melanoma skin cancers in hairy cell leukaemia: a Surveillance, Epidemiology and End Results population analysis and the 30â€year experience at Memorial Sloan Kettering Cancer Center. British Journal of Haematology, 2015, 171, 84-90.	2.5	14
168	Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma. Blood, 2015, 125, 2579-2581.	1.4	111
169	Intestinal Blautia Is Associated with Reduced Death from Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2015, 21, 1373-1383.	2.0	619
170	Intensified Mycophenolate Mofetil Dosing and Higher Mycophenolic Acid Trough Levels Reduce Severe Acute Graft-versus-Host Disease after Double-Unit Cord Blood Transplantation. Biology of Blood and Marrow Transplantation, 2015, 21, 920-925.	2.0	33
171	Non-myeloablative allogeneic hematopoietic stem cell transplantation for adults with relapsed and refractory mantle cell lymphoma: a single-center analysis in the rituximab era. Bone Marrow Transplantation, 2015, 50, 1293-1298.	2.4	15
172	Robust Vaccine Responses in Adult and Pediatric Cord Blood Transplantation Recipients Treated for Hematologic Malignancies. Biology of Blood and Marrow Transplantation, 2015, 21, 2160-2166.	2.0	31
173	Ovarian vein thrombosis after debulking surgery for ovarian cancer: epidemiology and clinical significance. American Journal of Obstetrics and Gynecology, 2015, 213, 208.e1-208.e4.	1.3	13
174	High Disease-Free Survival with Enhanced Protection against Relapse after Double-Unit Cord Blood Transplantation When Compared with T Cellâ€“Depleted Unrelated Donor Transplantation in Patients with Acute Leukemia and Chronic Myelogenous Leukemia. Biology of Blood and Marrow Transplantation, 2015, 21, 1985-1993.	2.0	40
175	Second Autologous Stem Cell Transplant: An Effective Therapy for Relapsed Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2015, 21, 468-472.	2.0	29
176	Hairy Cell Leukemia Variant Has Similar Survival to Classical Disease Despite Poorer Responses to Initial Therapy: A 30-Year Experience from Memorial Sloan Kettering Cancer Center. Blood, 2015, 126, 1476-1476.	1.4	2
177	Presence of PD-1 Expressing T Cells Predicts for Inferior Overall Survival in Newly Diagnosed Multiple Myeloma. Blood, 2015, 126, 1785-1785.	1.4	4
178	T Cell Exhaustion/Senescence in Relapsed Multiple Myeloma after Autologous Stem Cell Transplantation. Blood, 2015, 126, 1966-1966.	1.4	2
179	Reduced Emergency Room Utilization for Initiation of Anticoagulation with Rivaroxaban Versus Low Molecular Weight Heparin for Treatment of Cancer-Associated Thrombosis. Blood, 2015, 126, 2068-2068.	1.4	2
180	Biomarkers of Cardiotoxicity Among Multiple Myeloma Patients Subsequently Treated with Proteasome Inhibitor Therapy. Blood, 2015, 126, 4257-4257.	1.4	8

#	Article	IF	Citations
181	Incidence and Management of Proteasome Inhibitor-Related Cardiotoxicity in Multiple Myeloma Patients at Memorial Sloan Kettering Cancer Center. Blood, 2015, 126, 4265-4265.	1.4	6
182	Impact of Busulphan Exposure on Transplant Outcomes for Patients with Advanced Myelodysplastic Syndromes Undergoing CD34 Selected Allogeneic Hematopoietic Cell Transplantation. Blood, 2015, 126, 1911-1911.	1.4	3
183	Age-Adjusted Co-Morbidity Score - but Not Revised Disease Risk Index - Is Associated with Progression-Free Survival after Intermediate Intensity Double Unit CBT in Adults with Hematologic Malignancies. Blood, 2015, 126, 3231-3231.	1.4	0
184	Effects of Obesity on the Efficacy and Toxicity of Induction Chemotherapy in Adult Acute Lymphoblastic Leukemia (ALL). Blood, 2015, 126, 1290-1290.	1.4	0
185	Autologous Hematopoietic Stem Cell Transplantation Overcomes Primary Refractory Disease in Multiple Myeloma Patients Treated with Novel Agents. Blood, 2015, 126, 1996-1996.	1.4	5
186	Hypoalbuminemia Is Significantly Associated with Increased Clearance Time of High Doses of Methotrexate. Blood, 2015, 126, 3711-3711.	1.4	2
187	Fractionated Infusion of Hematopoietic Progenitor Cells Does Not Improve Neutrophil Recovery or Survival in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies. Blood, 2015, 126, 3095-3095.	1.4	0
188	Next-Generation Sequencing of Matched Normal Blood Identifies Clonal Hematopoiesis in a Significant Subset of Solid Tumor Patients without Hematologic Malignancies. Blood, 2015, 126, 2447-2447.	1.4	0
189	Targeted Sequencing Reveals a Relationship Between Mutational Burden and Clinical Phenotype in MPNs. Blood, 2015, 126, 4061-4061.	1.4	0
190	Response to Hypomethylating Agent Therapy in Acute Myeloid Leukemia Based upon Mutations in the DNA Methylation Pathway. Blood, 2015, 126, 2522-2522.	1.4	0
191	A Prospective Study of Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed/ Refractory Hodgkin Lymphoma. Blood, 2015, 126, 4383-4383.	1.4	0
192	Autologous Transplant, and Not ATO Alone, Remains the Preferred Therapy for Relapsed APL: A Report from the CIBMTR, EBMT and Two Specialized Centers. Blood, 2015, 126, 928-928.	1.4	0
193	Outcomes of Inferior Vena Cava Filter Placement in a Large Population of Cancer Patients Diagnosed with Pulmonary Embolism: Risk for Recurrent Venous Thromboembolism, Survival, and Filter-Related Complications. Blood, 2015, 126, 1112-1112.	1.4	0
194	A Phase II Study of a Nonmyeloablative Allogeneic Stem Cell Transplant with Peritransplant Rituximab in Patients with BÂCell Lymphoid Malignancies: Favorably Durable Event-Free Survival in Chemosensitive Patients. Biology of Blood and Marrow Transplantation, 2014, 20, 354-360.	2.0	35
195	Pretransplantation Fluorine-18-Deoxyglucoseâ€“Positron Emission Tomography Scan Lacks Prognostic Value in Chemosensitive B Cell Non-Hodgkin Lymphoma Patients Undergoing Nonmyeloablative Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2014, 20, 881-884.	2.0	28
196	Frequent Human Herpesvirus-6 Viremia But Low Incidence of Encephalitis in Double-Unit Cord Blood Recipients Transplanted Without Antithymocyte Globulin. Biology of Blood and Marrow Transplantation, 2014, 20, 787-793.	2.0	43
197	â€œNo Washâ€•Albumin-Dextran Dilution for Double-Unit Cord Blood Transplantation is Safe with High Rates of Sustained Donor Engraftment. Biology of Blood and Marrow Transplantation, 2014, 20, 490-494.	2.0	18
198	Dominant unit CD34+ cell dose predicts engraftment after double-unit cord blood transplantation and is influenced by bank practice. Blood, 2014, 124, 2905-2912.	1.4	74

#	Article	IF	Citations
199	Multiple copies of MLL as a commonly detected cytogenetic abnormality in newly diagnosed symptomatic multiple myeloma.. Journal of Clinical Oncology, 2014, 32, e19585-e19585.	1.6	1
200	Robustness of Approaches to ROC Curve Modeling under Misspecification of the Underlying Probability Model. Communications in Statistics - Theory and Methods, 2013, 42, 3655-3664.	1.0	3
201	Higher Mycophenolic Acid (MPA) Trough Levels Result In Lower Day 100 Severe Acute GVHD Without Increased Toxicity In Double-Unit Cord Blood Transplantation (CBT) Recipients. Blood, 2013, 122, 3297-3297.	1.4	1
202	Predicting Therapy-Related Acute Myeloid Leukemia By Routine Laboratory Values: An Analysis Of 126 Patients With Breast Cancer Referred For Bone Marrow Biopsy At Memorial Sloan-Kettering Cancer Center. Blood, 2013, 122, 2661-2661.	1.4	0
203	A High Complete Remission Rate Can Be Achieved In Older Patients (Age â‰¥60) With Acute Lymphoblastic Leukemia Regardless Of Induction Intensities: Single-Institution Experience At Memorial Sloan-Kettering Cancer Center. Blood, 2013, 122, 2638-2638.	1.4	0
204	Comprehensive Mutational Profiling In Myelodysplastic Syndromes Treated With Decitabine and Tretinoin. Blood, 2013, 122, 2791-2791.	1.4	0
205	Increased Incidence Of Melanoma and Non-Melanoma Skin Cancers In Patients With Hairy Cell Leukemia: A Single Institution Experience With 267 Patients From Memorial Sloan-Kettering Cancer Center. Blood, 2013, 122, 5274-5274.	1.4	0
206	Multiparameter Flow Cytometry For Detection Of Minimal Residual Disease In Multiple Myeloma After T-Cell Depleted Allogeneic Stem Cell Transplant. Blood, 2013, 122, 4647-4647.	1.4	0
207	Risk-Adapted Melphalan and Stem Cell Transplant for Systemic Light Chain Amyloidosis: A Single Institution Experience.. Blood, 2012, 120, 3109-3109.	1.4	2
208	Poor Graft Function in Recipients of T Cell Depleted (TCD) Allogeneic Hematopoietic Stem Cell Transplants (HSCT) Is Mostly Related to Viral Infections and Anti-Viral Therapy.. Blood, 2012, 120, 3147-3147.	1.4	5
209	Cryotherapy Reduces Mucositis in Multiple Myeloma Patients Receiving High-Dose Melphalan Conditioning Prior to Autologous Stem Cell Transplantation. Blood, 2012, 120, 4265-4265.	1.4	1
210	Phase II Study of Infusional Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma. Blood, 2012, 120, 947-947.	1.4	27
211	Outcomes of patients older than 60 years with acute lymphoblastic leukemia: Survey from the Surveillance, Epidemiology, and End Results (SEER) program.. Journal of Clinical Oncology, 2012, 30, 6532-6532.	1.6	0
212	Aerobic Glycolysis Predicts Outcome in Early Chronic Lymphocytic Leukemia.. Blood, 2012, 120, 2482-2482.	1.4	1
213	Unrelated Donor T-Cell Depleted (TCD) Hematopoietic Stem Cell Transplantation (HSCT) for Patients with Advanced Myelodysplastic Syndromes (MDS): The MSKCC Experience. Blood, 2012, 120, 1996-1996.	1.4	0
214	Fractionated Stem Cell Infusions for Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplant. Blood, 2012, 120, 4550-4550.	1.4	0
215	Sirolimus, Tacrolimus and Low-Dose Methotrexate Based Graft-Versus-Host Disease (GVHD) Prophylaxis After Non-Ablative or Reduced Intensity Conditioning in Related and Unrelated Donor Allogeneic Stem Cell Transplantation: Decreased Severe Early aGVHD but Persistence of Late Acute Gvhd. Blood, 2012, 120, 4194-4194.	1.4	0